BUY Rating on Palvella Therapeutics: De-Risked SELVA Phase 3 Design Positions QTORIN Rapamycin for First-in-Class MLM Approval and Compelling Risk–Reward

Palvella Therapeutics received a Buy rating from analyst Sam Slutsky of LifeSci Capital, with a price target of $150. The positive outlook is based on the well-designed Phase 3 SELVA study for QTORIN rapamycin, which shows strong clinical and regulatory visibility. The trial's structure and FDA agreement enhance the likelihood of approval, potentially making QTORIN the first FDA-approved therapy for microcystic lymphatic malformations. Mizuho Securities also reiterated a Buy rating with a $205 target, highlighting a favorable risk-reward profile and commercial opportunity.